These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 30010109

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Targeting STAT3 restores BRAF inhibitor sensitivity through miR-759-3p in human cutaneous melanoma cells.
    Su Y, Yu Y, He D, Zhang J, Wang Z, Sun P, Chen Z.
    Int J Clin Exp Pathol; 2018; 11(5):2550-2560. PubMed ID: 31938368
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G.
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [Abstract] [Full Text] [Related]

  • 5. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma.
    Luo M, Wu L, Zhang K, Wang H, Wu S, O'Connell D, Gao T, Zhong H, Yang Y.
    Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601
    [Abstract] [Full Text] [Related]

  • 6. Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAFV600E mutation.
    Wang K, Li Y, Song N, Che X, Hou K, Xu L, Bai M, Wang Q, Wang Y, Zhou Y, Cao M, Liu Y, Zhang J.
    J Cell Biochem; 2019 Apr; 120(4):5315-5325. PubMed ID: 30320916
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.
    Liu F, Cao J, Wu J, Sullivan K, Shen J, Ryu B, Xu Z, Wei W, Cui R.
    J Invest Dermatol; 2013 Aug; 133(8):2041-9. PubMed ID: 23344460
    [Abstract] [Full Text] [Related]

  • 9. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.
    Díaz-Martínez M, Benito-Jardón L, Alonso L, Koetz-Ploch L, Hernando E, Teixidó J.
    Cancer Res; 2018 Feb 15; 78(4):1017-1030. PubMed ID: 29229605
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
    Feng JH, Nakagawa-Goto K, Lee KH, Shyur LF.
    Mol Cancer Ther; 2016 Jun 15; 15(6):1163-76. PubMed ID: 27048951
    [Abstract] [Full Text] [Related]

  • 12. miR-579-3p controls melanoma progression and resistance to target therapy.
    Fattore L, Mancini R, Acunzo M, Romano G, Laganà A, Pisanu ME, Malpicci D, Madonna G, Mallardo D, Capone M, Fulciniti F, Mazzucchelli L, Botti G, Croce CM, Ascierto PA, Ciliberto G.
    Proc Natl Acad Sci U S A; 2016 Aug 23; 113(34):E5005-13. PubMed ID: 27503895
    [Abstract] [Full Text] [Related]

  • 13. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
    Sinnberg T, Makino E, Krueger MA, Velic A, Macek B, Rothbauer U, Groll N, Pötz O, Czemmel S, Niessner H, Meier F, Ikenberg K, Garbe C, Schittek B.
    EBioMedicine; 2016 Jun 23; 8():132-149. PubMed ID: 27428425
    [Abstract] [Full Text] [Related]

  • 14. miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma.
    Grzywa TM, Klicka K, Paskal W, Dudkiewicz J, Wejman J, Pyzlak M, Włodarski PK.
    PLoS One; 2020 Jun 23; 15(6):e0234707. PubMed ID: 32555626
    [Abstract] [Full Text] [Related]

  • 15. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
    Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ.
    Oncotarget; 2016 Dec 13; 7(50):81995-82012. PubMed ID: 27835901
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
    Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R.
    Cancer Discov; 2013 Feb 13; 3(2):158-67. PubMed ID: 23242808
    [Abstract] [Full Text] [Related]

  • 18. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
    Kim JH, Ahn JH, Lee M.
    Cancer Res Treat; 2017 Oct 13; 49(4):947-959. PubMed ID: 28052651
    [Abstract] [Full Text] [Related]

  • 19. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, Atzori MG, Ceci C, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM.
    Biochem Pharmacol; 2015 May 01; 95(1):16-27. PubMed ID: 25795251
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM, Frederick DT, Sullivan RJ, Flaherty KT, Srivastava SK.
    Oncotarget; 2015 Dec 01; 6(38):40535-56. PubMed ID: 26497853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.